|
 |
AcapodeneThis page contains recent news articles, when available, and an overview of Acapodene but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.GTx officials had hoped this month to be launching Acapodene for the prevention of bone fractures in men undergoing hormone deprivation drug therapy for ... Memphis Daily News GTx CEO Blames FDA for Bone Drug Rejection: BioBuzz - Nov 2, 2009 Steiner said that the FDA previously had agreed to base its approval review on a single study showing acapodene could lower the risk of bone fracture in men ... TheStreet.com The Bull and Bear Story on GTx's Pending Drug Decision: BioBuzz - Oct 27, 2009 GTx is seeking acapodene's approval as a treatment to reduce the risk of bone fractures in prostate cancer patients undergoing treatment with testosterone ... TheStreet.com YRC Worldwide, LDK Solar: Midday Volume Plays - Nov 2, 2009 GTx (GTXI Quote) tumbled by 37 cents, or 16.2%, to $2.65 after the Food and Drug Administration rejected acapodene, asking GTx for additional clinical data ... TheStreet.com GTx shares fall on lack of update regarding cancer drug - Oct 30, 2009 Oct 30 (Reuters) - Shares of GTx Inc fell more than 13 percent after the bell, extending losses from regular trading hours, as it failed to provide an ... Forbes ì „ë¦½ì„ ì•” ì¹˜ë£Œì œ 시장 '확대ì?¼ë¡œ' - Nov 11, 2009 ...ë¡œ '아비ë?¼í…Œë¡ '(abiraterone), 'ì•„ì¹´í?¬ë?´'(acapodene), 'MDV3100', ì„ íƒ?ì ? 내피 수용체 길í•ì œë¡œ '진래ì?´'(Xinlay, atrasentan)와 'ZD4054' 등ì?´ ê¼½íž? 수 있다. ... 디지틀보사 New Report Just Published: World Prostate Cancer Therapeutics ... - Jul 7, 2009 ...in GPC Biotech II-83 Ipsen Enters into Partnership with GTx to Develop and Market Acapodene in Europe II-83 Egenix and Proteome Systems Collaborate to PR Newswire (press release) Schuler Buys Stake in GTx - Feb 2, 2009 He also mentioned the company’s pipeline, noting that GTx has the potential to file four new drug applications into 2011, “starting with Acapodene for the Memphis Daily News, Ford Motor, HJ Heinz, O’Reilly, Wyeth: US Equity Preview - Jan 25, 2009 GTx Inc. (GTXI US): The drugmaker that makes the breast- cancer treatment Acapodene reported fourth-quarter revenue of $3 million, or 48 percent less than Bloomberg GTx execs raise holdings - Feb 2, 2009 ...(The company formerly used the name Acapodene for the experimental drug it is developing. European authorities are involved because a European company, Trading Markets (press release), BUYINS.NET: Market Maker Surveillance Report. Top 6 Abnormal Price ... - Jan 23, 2009 The companys product candidate in clinical development includes ACAPODENE, a selective estrogen receptor modulator, which is in pivotal Phase III clinical Trading Markets (press release), 'Pitt' bullish on drug firm GTx - Dec 4, 2008 GTx has several other drugs under development, including a 20 milligram dose of Acapodene that it is testing for prevention of prostate cancer in high-risk Memphis Commercial Appeal, Losses no problem for stock of Memphis, Tenn.-based drug company GTx - Nov 11, 2008 GTx has grown to 144 employees as it prepares to launch and sell Acapodene. French pharmaceutical giant Ipsen, which works with GTx, plans to seek Trading Markets (press release), Premium Company Profile - GTx, Inc. - New Research Report on ... - Nov 14, 2008 GTx´s biggest contributor to sales growth out to 2010 will be the sales of Acapodene. Revenues from Acapodene are expected to increase from $79 million in Live-PR.com (Pressemitteilung), Venture Vision - Oct 13, 2008 But as GTx awaits approval of its prostate cancer drug Acapodene and muscle- and bone-strengthening drug Ostarine, its future should not worry Stevenson too Business Tennessee, BUYINS.NET: BWLD, CACB, CBAK, CPHL, GTXI, PLPC Have Also Been ... - Oct 9, 2008 The company's product candidate in clinical development includes ACAPODENE, a selective estrogen receptor modulator, which is in pivotal Phase III clinical Trading Markets (press release), BUYINS.NET: BBI, GTXI, ZUMZ, CCOP, POPN, NUSMF Have Been On BUYINS ... - Oct 8, 2008 The company's product candidate in clinical development includes ACAPODENE, a selective estrogen receptor modulator, which is in pivotal Phase III clinical Trading Markets (press release), -- Standalone(1) 2008 financial objectives raised Aug 28, 2008 On February 25, 2008 -- Ipsen announced that GTx Inc., from which it licensed the European rights for Acapodene(R) (toremifene citrate 80 mg) in SeptemberMarketWatch BUYINS.NET: AN, GET, TWP, SUF, GTXI, MPWR Have Been Removed From ... Aug 28, 2008 The company's product candidate in clinical development includes ACAPODENE, a selective estrogen receptor modulator, which is in pivotal Phase III clinicalTrading Markets (press release), Ipsen: JP Morgan reste à 'surpondérer'. Sep 1, 2008 ...avec le potentiel de court terme Adenuric & Acapodene restant à être activé et un potentiel haussier significatif issu du Taspoglutide', ajoute-t-il.Boursorama, Objectifs financiers « standalone » (1) pour l’année 2008 relevés Aug 28, 2008 Le 25 février 2008, Ipsen a annoncé que GTx Inc., a présenté les résultats de la première étude de phase III sur Acapodene ® (citrate de torémifène 80 mg),Business Wire (press release), GTx losses continue but drug hopes high - 06 Aug 2008 A large-scale test showed Acapodene reduced fracture rates among these men, but it still faces scrutiny from the US Food and Drug Administration. Memphis Commercial Appeal, *vwd/BUSINESS WIRE: Ipsen’s First Half 2008 Sales, Outlook for the ... - Jul 30, 2008 On February 25, 2008 – Ipsen announced that GTx Inc., from which it licensed the European rights for Acapodene^® (toremifene citrate 80 mg) in September ddp-direkt.de, Premium Company Profile - GTx, Inc. - New Research Report on ... - 02 Jul 2008 GTx´s biggest contributor to sales growth out to 2010 will be the sales of Acapodene. Revenues from Acapodene are expected to increase from $79 million in PR-Inside.com (Pressemitteilung), GTx shares fall on review of Acapodene treatment - May 23, 2008 GTx Inc. stock fell Friday after news from an independent review group delayed the submission of the company's Acapodene treatment to federal reviewers for Bizjournals.com, Health Winners & Losers: Vivus - May 23, 2008 Post a less-stellar trading session Friday was GTx GTXI, which said a late-stage study of prostate cancer drug Acapodene will continue after review by an TheStreet.com GTx forecasts larger-than-expected full-year loss - May 12, 2008 The company said that its projection includes prelaunch costs for lead candidate Acapodene, which is designed to treat side effects of androgen deprivation CNNMoney.com S&P Stock Picks and Pans: Yahoo, CA, Verigy, GTX - May 23, 2008 Phase III acapodene study in preventing prostate cancer in patients with HG PIN lesions will continue, with final data set for mid-'09. BusinessWeek GTx, Inc. Reports First Quarter 2008 Financial Results - May 12, 2008 GTx is developing ACAPODENE® (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, WELT ONLINE, GTx Appoints Kenneth S. Robinson, MD to the Board of Directors - May 6, 2008 GTx is developing ACAPODENE(R) (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, FOXBusiness Protalix BioTherapeutics to Present at Three International ... - May 23, 2008 An independent group determined that the Acapodene trial should continue based on an interim analysis of data. ImmunoGen, Inc. (NASDAQ: IMGN) recently Financial News USA (press release), Investor profits as GTx still in the red - Apr 8, 2008 And it plans this year to file an FDA new drug application for the use of its drug Acapodene against symptoms related to androgen deprivation therapy, commercialappeal.com (subscription), GTx, Inc.: A Diamond in a Mud Pit - Apr 2, 2008 One of the company’s most promising late-stage medicines is toremifene citrate, or Acapodene. It is used to help treat patients with advanced prostate Seeking Alpha, GTX initiated with "market outperform" - Mar 25, 2008 In a research note published this morning, the analysts mention that the company is currently developing Acapodene in a pivotal Phase III clinical trial for newratings.com, Analyst initiations: PCLN, GTXI, AKNS and NEXM - Mar 25, 2008 Rodman & Renshaw is positive on GTX Inc's (NASDAQ: GTXI) opportunity for Acapodene in prostate cancer and Ostarine for muscle wasting. BloggingStocks GTX Shares Rise on Analyst Outlook - Mar 25, 2008 He said the company's developing drug Acapodene could have potential for multiple uses on the market. The drug is being studied as a treatment for side Houston Chronicle, GTx Announces Upcoming Presentation of Toremifene Citrate 80 mg ... - Apr 8, 2008 GTx is developing ACAPODENE® (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, Business Wire (press release), GTx Announces Webcast of Corporate Presentation at the 28 th ... - 10 Mar 2008 The GTx presentation, which will highlight the company’s clinical development programs and the recently announced results of the ACAPODENE® 80 mg Phase III Business Wire (press release), Toremifene (Acapodene) Reduces Fracture Risk from Androgen ... - Feb 27, 2008 GTx here said toremifene (Acapodene), a selective estrogen receptor modulator, also had a favorable impact on bone mineral density, lipids, and androgen MedPage Today, GTx reports promising results for Acapodene drug - Feb 25, 2008 The company reported that an 80 milligram dose of the drug Acapodene caused a significant reduction in side effects for men undergoing a treatment for commercialappeal.com (subscription), GTx: Androgen therapy drug test positive - Mar 3, 2008 New Phase III data from tests of GTx Inc.'s Acapodene show that the 80 milligram dose of the drug reduces hot flashes in men with prostate cancer on Bizjournals.com, UPDATE: GTx Drug Cuts Side Effects In Cancer Therapy - Feb 25, 2008 In the study, Acapodene met its main goal of reducing osteoporosis-related vertebral fractures, a possible side effect of hormone therapy. CNNMoney.com GTx Surges on Late-Stage Trial Results - Feb 25, 2008 Shares of GTxGTXI soared nearly 50% Monday after the biopharmaceutical company said its Acapodene drug showed success in a late-stage study in reducing side TheStreet.com GTx: A Compelling Biotech - Feb 11, 2008 The company expects data from two phase III studies for its lead drug candidate, Acapodene, during the first quarter of 2008. BusinessWeek GTx drug cuts hot flashes - Mar 3, 2008 By Daniel Connolly Memphis pharmaceutical company GTx Inc. said Monday that its experimental drug Acapodene reduces hot flashes in men who are undergoing a commercialappeal.com (subscription), New drug's results 'exciting' for GTx - Feb 25, 2008 The successful testing of the pharmaceutical company's new drug -- Acapodene -- also boosts Memphis' effort to make biotechnology a cornerstone of economic commercialappeal.com (subscription), GTx Drug Gives Men Pause - Feb 25, 2008 The new drug will be called Acapodene. "This is very big for us. We've been on this trail for ten years, so to have a positive phase three is pretty Forbes, GTx shares up 40% on late-stage trial - Feb 25, 2008 GTx Inc. plans to file a New Drug Application with the Food and Drug Administration, after releasing key data about its 80 milligram dosage of Acapodene. Bizjournals.com, S&P Picks and Pans: EA, Take-Two - Feb 25, 2008 ...-S.Silver The shares are up sharply this morning as GTXI announces positive Phase III results for lead candidate Acapodene for treating side effects of BusinessWeek GTx loss widens in 4Q - Feb 19, 2008 ..."We continued to execute on our business plan in 2007 by advancing Acapodene and forging an important strategic SARM (selective androgen receptor modulator) Bizjournals.com, Ipsen says toremifene citrate meets targets in phase 3 trial - Feb 25, 2008 25, 2008 (Thomson Financial delivered by Newstex) -- Ipsen said Acapodene, or toremifene citrate, has met primary and key secondary endpoints in a phase III CNNMoney.com Ageless Makes Testosterone Treatments Affordable - Mar 3, 2008 Acapodene and Ostarine are being developed to counter the harshest side effects of chemotherapy by stimulating bone mass, muscle mass and appetite. Memphis Daily News, S&P analyst touts GTx products - Feb 12, 2008 Acapodene represents "a significant opportunity" in the treatment and prevention of prostate cancer and each dosage (20 and 80 milligrams) has greater than Bizjournals.com, Q4 2007 Earnings Call - Feb 19, 2008 As we have stated previously, we anticipate releasing top line results of our ACAPODENE 80mg Phase III ADT clinical trial and conducting the efficacy Seeking Alpha, GTX Inc. 4Q loss widens, revenue declines - Feb 19, 2008 The Memphis, Tenn. biopharmaceutical company said expects releasing top line results of the Acapodene 80 milligram Phase III ADT clinical trial by the end Forbes, GTx Phase 3: A Win for Prostate Cancer Sufferers and for ... - Feb 27, 2008 A few years back, as a consultant, I was asked by GTX (GTXI) to take a look at their unreleased Phase 2 ACAPODENE (toremifene citrate 80 mg) data and to Seeking Alpha, Pharma Sector: Few Newsmakers Of The Week - Wyeth, GTx, Allergan ... - Mar 8, 2008 The drug, which would be marketed under the brand name Acapodene, is in the same class as AstraZeneca's breast cancer drug tamoxifen and Eli Lilly's Evista, RTT News, Jacobs Engg. Receives District Of Columbia Consolidated Forensics ... - Feb 19, 2008 Mitchell Steiner, Chief Executive Officer of GTx, stated, “We are now focused on obtaining the top line results of the ACAPODENE 80 mg Phase III ADT RTT News, GTx Good News on ADT Gives its Stock a 36 Percent Boost - Feb 25, 2008 GTx Inc. said results from a Phase III study of its investigational drug Acapodene (toremifene citrate, 80 mg), showed that it works to reduce spinal Therapeutics Daily (subscription) (press release), Ipsen's Full Year 2007 Results and Financial Objectives for the ... - Feb 27, 2008 ...such as the phase III for Acapodene(R), phase II for our GLP-1 analogue partnered with Roche or phase I for our promising anti-tumor agent STX-64, FOXBusiness GTx's Toremifene Citrate 80 mg Meets Primary and Key Endpoints in ... - Feb 26, 2008 GTx is developing ACAPODENE(R) (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, FOXBusiness Ipsen: Toremifene Citrate 80 mg Meets Primary and Key Secondary ... - Feb 26, 2008 Ipsen (Paris:IPN) announced today that GTx Inc. (NASDAQ: GTXI), from which it licensed the European rights for Acapodene(R) (toremifene citrate 80 mg) in FOXBusiness Winners & Losers Monday's Health Winners & Losers - Feb 25, 2008 Also on the rise was GTxGTXI, which soared 39% to $18 after the company said its Acapodene drug was successful in reducing side effects of prostate cancer TheStreet.com GTx Announces Additional Top Line Phase III Data Demonstrating ... - Mar 3, 2008 GTx is developing ACAPODENE ® (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, Business Wire (press release), Ipsen lays out plans for another successful year in 2008 - Feb 28, 2008 He added that the recent publication of clinical results, such as the impressive Phase III data for the prostate cancer drug Acapodene (toremifene), Pharma Times (subscription), Results in line with the Group’s objectives - Feb 26, 2008 ...such as the phase III for Acapodene ® , phase II for our GLP-1 analogue partnered with Roche or phase I for our promising anti-tumor agent STX-64, Business Wire (press release), GTx and Ipsen cheered by Phase III data on toremifene - Feb 26, 2008 Stephane Thiroloix, executive vice president of corporate development at the French drugmaker, said that the drug, which Ipsen will sell as Acapodene, Pharma Times (subscription), Phase III Clinical Trial in Advanced Prostate Cancer Patients on ... - Feb 25, 2008 Ipsen (Paris:IPN) announced today that GTx Inc. (NASDAQ: GTXI), from which it licensed the European rights for Acapodene^® (toremifene citrate 80 mg) in Vereinigte Wirtschaftsdienste, |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
